Patients with Lebers hereditary optic neuropathy should not receive B12 due to the risk of optic nerve damage
it reports previously unpublished work
A.AnnunziataF.et al (2013)
Disclosures: Takumi Kawaguchi: ASKA Pharmaceutical Co., Ltd.: Speaking and Teaching, Taisho Pharmaceutical Co., Ltd.: Speaking and Teaching, Kowa Company, Ltd.: Speaking and Teaching, AbbVie GK.: Speaking and Teaching, Eisai Co., Ltd.: Speaking and Teaching, Novo Nordisk Pharma Ltd.: Speaking and Teaching, Janssen Pharmaceutical K.K.: Speaking and Teaching, Janssen Pharmaceutical K.K.: Speaking and Teaching, Otsuka Pharmaceutical Co., Ltd.: Speaking and Teaching, EA Pharma Co.,Ltd.: Speaking and Teaching, Kenta Murotani: Nothing to Disclose, Hiromitsu Kajiyama: Nothing to Disclose, Hitoshi Obara: Nothing to Disclose, Hironori Yamaguchi: Nothing to Disclose, Yuko Toyofuku: Nothing to Disclose, Fumi Kaneko: Nothing to Disclose, Yutaka Seino: Nothing to Disclose, Saeko Uchida: Nothing to Disclose 1602 CHANGING PRESCRIPTION PATTERN OF ANTI-DIABETIC MEDICATIONS AND IMPROVEMENT IN GLYCEMIC CONTROL IN PATIENTS WITH T2DM, WITH AND WITHOUT CIRRHOSIS: A TERRITORY-WIDE COHORT STUDY IN HONG KONG FROM 2000-2023 Mary Yue Wang 1 Sherlot Juan Song 1 Grace Lai-Hung Wong 1 Vincent Wong 1 Terry Cheuk-Fung Yip 1 , 1 The Chinese University of Hong Kong Background: We aimed to compare the secular trends of glycemic control and anti-diabetic medication use in patients with type 2 diabetes mellitus (T2DM), with and without cirrhosis in a retrospective cohort in Hong Kong
3 Angiosperms have the unique ability to synthesize numerous bioactive compounds that can be of medicinal and healthcare importance to humans
Amino Alchemy is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.
